<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00072332</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000339607</org_study_id>
    <secondary_id>MSKCC-03070</secondary_id>
    <secondary_id>PHARMACIA-EDOAES-2730-001</secondary_id>
    <nct_id>NCT00072332</nct_id>
  </id_info>
  <brief_title>Edotecarin and Cisplatin in Treating Patients With Advanced or Metastatic Solid Tumors</brief_title>
  <official_title>A Phase I Dose Escalation Study of Edotecarin (PHA-782615) and Cisplatin in Adult Patients With Advanced/Metastatic Solid Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Memorial Sloan Kettering Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy, such as edotecarin and cisplatin, use different ways&#xD;
      to stop tumor cells from dividing so they stop growing or die. Combining edotecarin with&#xD;
      cisplatin may kill more tumor cells.&#xD;
&#xD;
      PURPOSE: Phase I trial to study the effectiveness of combining edotecarin with cisplatin in&#xD;
      treating patients who have advanced or metastatic solid tumors.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      Primary&#xD;
&#xD;
        -  Determine the maximum tolerated dose and recommended phase II dose of edotecarin when&#xD;
           administered with cisplatin (administered in 2 different schedules) in patients with&#xD;
           advanced or metastatic solid tumors.&#xD;
&#xD;
      Secondary&#xD;
&#xD;
        -  Determine the safety profile of this regimen in these patients.&#xD;
&#xD;
        -  Determine the plasma pharmacokinetics of this regimen in these patients.&#xD;
&#xD;
        -  Determine the antitumor activity of this regimen in these patients.&#xD;
&#xD;
      OUTLINE: This is an open-label, multicenter, dose-escalation study of edotecarin. Patients&#xD;
      are assigned to 1 of 2 schedules.&#xD;
&#xD;
        -  Schedule A: Patients receive cisplatin IV over 30 minutes and edotecarin IV over 1 hour&#xD;
           on days 1 and 8.&#xD;
&#xD;
        -  Schedule B: Patients receive cisplatin IV over 2 hours and edotecarin IV over 1 hour on&#xD;
           day 1.&#xD;
&#xD;
      In both schedules, courses repeat every 3 weeks in the absence of disease progression or&#xD;
      unacceptable toxicity.&#xD;
&#xD;
      Cohorts of 3-6 patients in each schedule receive escalating doses of edotecarin until the&#xD;
      maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at&#xD;
      which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity. Once the MTD is&#xD;
      determined, 10 additional patients with metastatic esophageal or gastric cancer receive&#xD;
      treatment as above at the MTD.&#xD;
&#xD;
      Patients are followed every 2 months for 1 year or until disease progression.&#xD;
&#xD;
      PROJECTED ACCRUAL: A maximum of 80 patients (40 per schedule) will be accrued for this study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2003</start_date>
  <completion_date type="Actual">December 2009</completion_date>
  <primary_completion_date type="Actual">December 2005</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <condition>Esophageal Cancer</condition>
  <condition>Gastric Cancer</condition>
  <condition>Unspecified Adult Solid Tumor, Protocol Specific</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cisplatin</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>edotecarin</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Diagnosis of one of the following:&#xD;
&#xD;
               -  Histologically or cytologically confirmed active solid tumor malignancy&#xD;
&#xD;
               -  Histologically confirmed esophageal or gastric cancer* meeting all the following&#xD;
                  criteria:&#xD;
&#xD;
                    -  Previously untreated disease&#xD;
&#xD;
                    -  Metastatic disease&#xD;
&#xD;
                    -  Measurable disease&#xD;
&#xD;
                         -  At least 1 unidimensionally measurable lesion at least 20 mm by&#xD;
                            conventional techniques OR 10 mm by spiral CT scan NOTE: *Patients with&#xD;
                            esophageal or gastric cancer are enrolled after the maximum tolerated&#xD;
                            dose has been determined&#xD;
&#xD;
          -  No known brain or leptomeningeal disease&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age&#xD;
&#xD;
          -  18 and over&#xD;
&#xD;
        Performance status&#xD;
&#xD;
          -  ECOG 0-1&#xD;
&#xD;
        Life expectancy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Hematopoietic&#xD;
&#xD;
          -  Absolute neutrophil count at least 1,500/mm^3&#xD;
&#xD;
          -  Platelet count at least 100,000/mm^3&#xD;
&#xD;
          -  Hemoglobin at least 9.0 g/dL&#xD;
&#xD;
        Hepatic&#xD;
&#xD;
          -  Bilirubin no greater than 1.5 times upper limit of normal (ULN) (regardless of liver&#xD;
             involvement by tumor)&#xD;
&#xD;
          -  SGOT no greater than 3 times ULN (5 times ULN if there is liver involvement by tumor)&#xD;
&#xD;
          -  Albumin at least 3.0 g/dL&#xD;
&#xD;
        Renal&#xD;
&#xD;
          -  Creatinine no greater than 1.5 mg/dL&#xD;
&#xD;
        Cardiovascular&#xD;
&#xD;
          -  None of the following within the past 12 months:&#xD;
&#xD;
               -  Myocardial infarction&#xD;
&#xD;
               -  Severe/unstable angina&#xD;
&#xD;
               -  Symptomatic congestive heart failure&#xD;
&#xD;
               -  Cerebrovascular accident&#xD;
&#xD;
               -  Transient ischemic attack&#xD;
&#xD;
               -  Deep vein thrombosis&#xD;
&#xD;
               -  Other significant thromboembolic event&#xD;
&#xD;
          -  No ongoing grade 2 or greater cardiac dysrhythmia&#xD;
&#xD;
          -  No atrial fibrillation&#xD;
&#xD;
        Pulmonary&#xD;
&#xD;
          -  No pulmonary embolism within the past 12 months&#xD;
&#xD;
        Gastrointestinal&#xD;
&#xD;
          -  No active inflammatory bowel disease&#xD;
&#xD;
          -  No partial or complete bowel obstruction&#xD;
&#xD;
          -  No chronic diarrhea&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception&#xD;
&#xD;
          -  HIV negative&#xD;
&#xD;
          -  No grade 2 or greater acute toxic effects&#xD;
&#xD;
          -  No active infection&#xD;
&#xD;
          -  No other concurrent acute or chronic medical or psychiatric condition or laboratory&#xD;
             abnormality that would preclude study participation&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy&#xD;
&#xD;
          -  No prior treatment with any of the following systemic therapies for metastatic&#xD;
             cancer*:&#xD;
&#xD;
               -  Antibody therapy&#xD;
&#xD;
               -  Immunotherapy&#xD;
&#xD;
               -  Gene therapy&#xD;
&#xD;
               -  Vaccine therapy&#xD;
&#xD;
               -  Cytokine therapy&#xD;
&#xD;
               -  Inhibitors of vascular endothelial growth factor/Flk-1 pathway&#xD;
&#xD;
          -  No concurrent sargramostim (GM-CSF)&#xD;
&#xD;
          -  No concurrent antibody therapy or immunotherapy NOTE: *Patients with esophageal or&#xD;
             gastric cancer only&#xD;
&#xD;
        Chemotherapy&#xD;
&#xD;
          -  No more than 1 prior chemotherapy regimen for metastatic disease*&#xD;
&#xD;
          -  No prior high-dose chemotherapy requiring hematopoietic stem cell rescue&#xD;
&#xD;
          -  No other concurrent chemotherapy NOTE: *No prior chemotherapy for metastatic disease&#xD;
             for patients with esophageal or gastric cancer&#xD;
&#xD;
        Endocrine therapy&#xD;
&#xD;
          -  No concurrent hormonal treatment&#xD;
&#xD;
        Radiotherapy&#xD;
&#xD;
          -  No prior radiotherapy to more than 25% of bone marrow reserve&#xD;
&#xD;
          -  No prior radiotherapy to the sole measurable lesion*&#xD;
&#xD;
          -  No concurrent radiotherapy NOTE: *Patients with esophageal or gastric cancer only&#xD;
&#xD;
        Surgery&#xD;
&#xD;
          -  More than 12 months since prior coronary/peripheral artery bypass graft surgery&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  Recovered from prior therapy&#xD;
&#xD;
          -  More than 6 months since last dose of prior adjuvant therapy*&#xD;
&#xD;
          -  No prior treatment with any of the following systemic therapies for metastatic&#xD;
             cancer*:&#xD;
&#xD;
               -  Cyclooxygenase-2 inhibitors&#xD;
&#xD;
               -  Matrix metalloprotease inhibitors&#xD;
&#xD;
               -  Epidermal growth factor receptor inhibitors&#xD;
&#xD;
               -  Other experimental agents&#xD;
&#xD;
          -  No other concurrent anticancer therapy&#xD;
&#xD;
          -  No concurrent enrollment in another clinical trial&#xD;
&#xD;
          -  No other concurrent experimental drugs NOTE: *Patients with esophageal or gastric&#xD;
             cancer only&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David H. Ilson, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Memorial Sloan Kettering Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Memorial Sloan-Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10021</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2009</verification_date>
  <study_first_submitted>November 4, 2003</study_first_submitted>
  <study_first_submitted_qc>November 5, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 6, 2003</study_first_posted>
  <last_update_submitted>December 18, 2013</last_update_submitted>
  <last_update_submitted_qc>December 18, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 19, 2013</last_update_posted>
  <keyword>unspecified adult solid tumor, protocol specific</keyword>
  <keyword>stage IV esophageal cancer</keyword>
  <keyword>stage IV gastric cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stomach Neoplasms</mesh_term>
    <mesh_term>Esophageal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cisplatin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

